MADISON, Wisconsin, February. 19: -- Nimble Therapeutics, has revealed a multi-year partnership with Genentech, a member of the Roche Group, to expedite discovery and development of novel peptide-based medicines for targets across an of ailments.
The partnership will leverage Nimble's proprietary peptide synthesis, screening and optimization platform, chemical variety, and combined suite of assays to allow swifter discovery and optimization of impressive compounds for intracellular and extracellular targets.
"We are excited to collaborate with a world class and well-respected organization such as Genentech to identify novel peptide therapeutics," observed Jigar Patel, Ph.D., Chief Executive Officer of Nimble Therapeutics. "This partnership combines the strengths of our two organizations to potentially bring new medicines to patients."
Under the condition of the agreement, Nimble will obtain an unknown upfront payment and will be fit for downstream milestone payments and royalties.
About Nimble Therapeutics
Nimble Therapeutics is bringing the strength of parallel chemical synthesis to drug discovery. Nimble's proprietary expertise permits the fast synthesis, screening and engineering of millions of scaffolded natural and modified macrocyclic peptidomimetics. Nimble has also evolved a number of biological assays that assist in the empirical screening and optimization of molecules with more preferable drug-like properties. The company is developing collaborations with top pharmaceutical companies to balance its expertise across numerous therapeutic spheres.
By ANJISHNU BISWAS
No comments:
Post a Comment